The use patterns of novel psychedelics: experiential fingerprints of substituted phenethylamines, tryptamines and lysergamides.
Psychopharmacology June 1, 2022 P Mallaroni, N L Mason, F R J Vinckenbosch et al. 16 citations
Novel psychedelics (NPs) are a growing group of compounds with unknown use profiles and subjective effects. A survey of 1,180 NP users examined usage patterns and adverse events for three structural families: phenethylamines, tryptamines, and lysergamides. Novel phenethylamines were most prevalent (61.5%), followed by tryptamines (43.8%) and lysergamides (42.9%). Compared to phenethylamines, tryptamine and lysergamide users had significantly fewer physical adverse events, but no significant differences in psychological adverse events appeared. A machine-learning classifier distinguished three specific compounds—2C-B, 1P-LSD, and 4-AcO-DMT—with moderate accuracy (AUC 0.79). The findings suggest NP classes may differ in adverse event rates and phenomenology, though subjective experience may blur distinctions.